1. Home
  2. AGIO vs STC Comparison

AGIO vs STC Comparison

Compare AGIO & STC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • STC
  • Stock Information
  • Founded
  • AGIO 2007
  • STC 1893
  • Country
  • AGIO United States
  • STC United States
  • Employees
  • AGIO N/A
  • STC N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • STC Specialty Insurers
  • Sector
  • AGIO Health Care
  • STC Finance
  • Exchange
  • AGIO Nasdaq
  • STC Nasdaq
  • Market Cap
  • AGIO 2.1B
  • STC 2.0B
  • IPO Year
  • AGIO 2013
  • STC N/A
  • Fundamental
  • Price
  • AGIO $36.39
  • STC $74.40
  • Analyst Decision
  • AGIO Buy
  • STC Buy
  • Analyst Count
  • AGIO 6
  • STC 2
  • Target Price
  • AGIO $57.00
  • STC $77.50
  • AVG Volume (30 Days)
  • AGIO 771.2K
  • STC 136.4K
  • Earning Date
  • AGIO 10-30-2025
  • STC 10-22-2025
  • Dividend Yield
  • AGIO N/A
  • STC 2.68%
  • EPS Growth
  • AGIO N/A
  • STC 99.80
  • EPS
  • AGIO 11.13
  • STC 3.11
  • Revenue
  • AGIO $40,875,000.00
  • STC $2,668,739,000.00
  • Revenue This Year
  • AGIO $28.19
  • STC $13.62
  • Revenue Next Year
  • AGIO $152.14
  • STC $12.41
  • P/E Ratio
  • AGIO $3.27
  • STC $23.94
  • Revenue Growth
  • AGIO 30.57
  • STC 13.92
  • 52 Week Low
  • AGIO $23.42
  • STC $56.39
  • 52 Week High
  • AGIO $62.58
  • STC $78.44
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 51.16
  • STC 60.68
  • Support Level
  • AGIO N/A
  • STC $71.44
  • Resistance Level
  • AGIO $37.18
  • STC $75.19
  • Average True Range (ATR)
  • AGIO 1.43
  • STC 1.76
  • MACD
  • AGIO -1.50
  • STC -0.12
  • Stochastic Oscillator
  • AGIO 88.53
  • STC 79.24

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

Share on Social Networks: